Construction method of oral squamous cell carcinoma double-sulfur death related DNA methylation prognosis model

By constructing a prognosis model of disulfide death-related DNA methylation in oral squamous cell carcinoma, using differential DNA methylation sites and COX regression analysis, the problem of insufficient research on the prognosis model of oral squamous cell carcinoma in the prior art was solved. Improved prognosis accuracy and treatment effect.

CN118919074APending Publication Date: 2024-11-08HAINAN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410955172.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, there are few researches on disulfide death-related prognosis models based on oral squamous cell carcinoma, and it is difficult to comprehensively evaluate the survival status and disease development trend of cancer cells, affecting the treatment effect and prognosis accuracy.

Method used

By obtaining the collection of differential DNA methylation sites related to disulfide death, a prognosis model of disulfide death-related DNA methylation in oral squamous cell carcinoma was constructed, and data integration, preprocessing, differential site screening and COX were used for data integration, preprocessing, and differential site screening and COX. Regression analysis, risk scoring formula was constructed to evaluate patient survival prognosis.

Benefits of technology

It improves the accuracy of predicting the survival prognosis of patients with oral squamous cell carcinoma, helps doctors formulate personalized treatment plans, improve treatment effects and reduce treatment risks, and provides more accurate understanding of the disease and quality of life improvement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118919074A_ABST
    Figure CN118919074A_ABST
Patent Text Reader

Abstract

The invention provides an oral squamous cell carcinoma double-sulfur death related DNA methylation prognosis model construction method, and relates to the technical field of molecular biology, and the method comprises the following steps: S101, obtaining a double-sulfur death related differential DNA methylation site set; and S102, on the basis of the differential DNA methylation sites, constructing a DNA methylation prognosis model related to the OSCC (Oral squamous cell carcinoma) double-sulfur death. According to the method, the OSCC patient prognosis model is constructed on the basis of differential DNA methylation sites related to disulphide death, and the survival state of OSCC cancer cells and the development trend of diseases can be evaluated more comprehensively, so that the accuracy of predicting the survival prognosis condition of the patient is improved, doctors are helped to formulate a more personalized treatment scheme, and the clinical application prospect is broad. The treatment risk is reduced while the treatment effect is improved, the accurate prognosis prediction can help the patient to better know the illness state and prognosis of the patient, and the treatment effect and life quality of the patient are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of molecular biology, and in particular to a method for constructing a disulfide death-related DNA methylation prognostic model for oral squamous cell carcinoma. Background Art

[0002] Oral squamous cell carcinoma (OSCC) is a malignant tumor originating from the squamous epithelium of the oral mucosa. It usually occurs in the tongue, floor of the mouth, buccal mucosa, lips, gums and other parts. OSCC is the most common type of oral cancer, accounting for more than 90% of all oral cancers. If OSCC is not treated promptly and effectively, cancer cells will continue to spread and metastasize, eventually threatening the patient's life. The cancer prognosis model is a prediction model established by analyzing the patient's clinical data, biological information and other information, using statistical and machine learning methods, aiming to evaluate the prognosis of cancer patients and their influencing factors. This model can help doctors and patients better understand the development trend of the disease and provide a reference for the selection of treatment options. Disulfide death is a new type of cell death caused by disulfide stress caused by excessive cystine accumulation. The discovery and study of disulfide death provides a new perspective for understanding the mechanism of cell death, and also provides new possible strategies for the treatment of diseases such as cancer. At present, there are few studies on the prognostic model of oral squamous cell carcinoma based on disulfide death. Summary of the invention

[0003] In view of this, the purpose of the present invention is to provide a method for constructing a disulfide death-related DNA methylation prognostic model for oral squamous cell carcinoma, so as to evaluate the survival prognosis of OSCC patients from the perspective of disulfide death.

[0004] To achieve the above-mentioned purpose of the invention, the present invention provides a method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma, the method comprising the following steps:

[0005] S101, obtaining a set of differential DNA methylation sites associated with disulfide death;

[0006] S102. Construct a disulfide death-related DNA methylation prognostic model for OSCC (oral squamous cell carcinoma) based on differential DNA methylation sites.

[0007] Furthermore, step S101 specifically includes the following steps:

[0008] S201. Screen out the sites with high or low methylation in multiple cohorts from the OSCC significantly differentially expressed DNA methylation sites, and then screen out the methylation sites located in the promoter region;

[0009] S202, obtaining disulfide death-related genes from whole-genome CRISPR-Cas9 sequencing results;

[0010] S203. Using R software, the genes corresponding to the OSCC differential DNA methylation sites in the promoter region are intersected with the disulfide death-related genes to obtain a differential DNA methylation site set.

[0011] Furthermore, the promoter region includes 5'UTR, TSS200, TSS1500 and 1st Exon.

[0012] Furthermore, the OSCC significantly differentially expressed DNA methylation sites were obtained by the following steps:

[0013] S301. Obtain DNA methylation data and clinical data of HNSCC (head and neck squamous cell carcinoma) patients, and delete DNA methylation data without clinical information and non-oral sites;

[0014] S302, acquiring a DNA methylation data set based on preset inclusion criteria;

[0015] S303, integrating all DNA methylation data obtained in steps S301 and S302, and then performing preprocessing, quality control filtering and normalization on the integrated DNA methylation data;

[0016] S304. Differential methylation analysis was performed on OSCC tissues and normal oral tissues in the TCGA database using R software. The screening conditions for differential sites were |logFC|>0.1, P<0.05 and false discovery rate (FDR)<0.05.

[0017] S305. Run R software to recalculate the OSCC differential DNA methylation sites in multiple different cohorts to obtain the Meta P value, and use the Benjamini-Hochberg method to correct the Meta P value obtained for each site. The FDR is 5%. The setting standard for OSCC significantly differential DNA methylation sites is single CpG: |logFC|>0.1, FDR<0.05, and output OSCC significantly differential DNA methylation sites.

[0018] Furthermore, the preset inclusion criteria include: oral tissues of OSCC patients, the same DNA methylation sequencing platform, normal oral tissues, and patients who have not received chemoradiotherapy or biological treatment.

[0019] Furthermore, step S102 specifically includes the following steps:

[0020] S401, selecting the top N disulfide death-related DNA methylation sites from the differential DNA methylation site set for analysis, and merging the clinical data of M patients with the N disulfide death-related DNA methylation sites using R software to obtain merged data;

[0021] S402. Using R software, we took survival status as the prognostic type and P<0.05 as the threshold value to perform multivariate COX regression analysis on the combined data, screened out the disulfide death-related DNA methylation sites that were closely related to the survival prognosis of OSCC patients, calculated their hazard ratio (HR) and 95% confidence interval (95% CI), and drew a hazard ratio forest plot;

[0022] S403. A model was constructed based on the disulfide death DNA methylation level and the corresponding COX regression coefficient, which is closely related to the survival prognosis of OSCC patients. The risk score formula is as follows:

[0023]

[0024] Where N is the number of prognosis-related DNA methylation sites, Meth i is the DNA methylation level, Coef i is the COX regression coefficient.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The method provided by the present invention constructs a prognostic model for OSCC patients based on differential DNA methylation sites associated with disulfide death. As an emerging cell death mode, disulfide death is closely related to the progression and prognosis of oral squamous cell carcinoma. Considering the disulfide death mechanism, the survival status of OSCC cancer cells and the development trend of the disease can be more comprehensively evaluated, thereby improving the accuracy of predicting the patient's survival prognosis, helping doctors to formulate more personalized treatment plans, improving the treatment effect while reducing the treatment risk, and accurate prognosis prediction can help patients better understand their condition and prognosis, improve their treatment effect and quality of life. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only preferred embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0028] Figure 1 It is a schematic diagram of the overall process of a method for constructing a disulfide death-related DNA methylation prognostic model for oral squamous cell carcinoma provided by an embodiment of the present invention.

[0029] Figure 2 It is a schematic diagram of the process of obtaining a differential DNA methylation site set provided by an embodiment of the present invention.

[0030] Figure 3 It is a schematic diagram of the process of obtaining DNA methylation sites with significant differences in OSCC provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0031] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The enumerated embodiments are only used to explain the present invention and are not used to limit the scope of the present invention.

[0032] Reference Figure 1 This embodiment provides a method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma, the method comprising the following steps:

[0033] S101. Obtain a set of differential DNA methylation sites associated with disulfide death.

[0034] S102. Construct a disulfide death-related DNA methylation prognostic model for OSCC (oral squamous cell carcinoma) based on differential DNA methylation sites.

[0035] As an optional implementation, refer to Figure 2 , obtaining a set of differential DNA methylation sites associated with disulfide death can be achieved by following the steps below:

[0036] S201, from the OSCC significantly different DNA methylation sites, the sites that are hypermethylated or hypomethylated in multiple queues are screened, and then the methylation sites located in the promoter region are screened. In this embodiment, the hypermethylated or hypomethylated sites are screened from 5 queues respectively. Exemplarily, the promoter region includes 5'UTR, TSS200, TSS1500 and 1st Exon.

[0037] S202. 18012 disulfide death-related genes were obtained from the whole-genome CRISPR-Cas9 sequencing results.

[0038] S203. Using R software, the genes corresponding to the OSCC differential DNA methylation sites in the promoter region are intersected with the disulfide death-related genes to obtain a differential DNA methylation site set.

[0039] As a further optional embodiment, refer to Figure 3 In step S201, the OSCC significantly differentially methylated sites are obtained by the following steps:

[0040] S301. Obtain DNA methylation data and clinical data of HNSCC (head and neck squamous cell carcinoma) patients, and delete DNA methylation data without clinical information and non-oral parts.

[0041] Exemplarily, DNA methylation data and clinical data of HNSCC patients can be downloaded from the TCGA database, and the DNA methylation data and clinical data can be selected based on the Ilumina Huaman Methylation 450K sequencing platform.

[0042] S302. Based on the preset inclusion criteria, obtain a DNA methylation dataset.

[0043] Exemplarily, the preset inclusion criteria include: 1. oral tissue of OSCC patients; 2. the same DNA methylation sequencing platform; 3. normal oral tissue; 4. patients who have not received chemoradiotherapy or biological treatment.

[0044] S303, integrating all DNA methylation data obtained in steps S301 and S302, and then performing preprocessing, quality control filtering and normalization processing on the integrated DNA methylation data.

[0045] In some implementations, the DNA methylation data is preprocessed, quality controlled and filtered, and normalized by running the R software package "minfi". The specific workflow is as follows:

[0046] The Illumina methylation 450K chip data idat and phenotype data read through the sample information were organized into the "RGChannelSet" type and preprocessed using Preprocess Quantile. After preprocessing, the Dectection P of the methylation probe was calculated after conversion to the "Genomic Ratio Set" type, and the quality control was performed by calculating the average Detection P of the probe, and the data with an average less than Detection P < 0.01 were retained. The R software package "ComBat" was run to correct the batch effect of the data and normalize it. The methylation degree of each probe was calculated and presented in the form of methylation value (β value), and the β value was M / (M+U), where M was the methylated probe intensity and U was the unmethylated probe intensity. Then, probe filtering was continued to remove probes that hybridized with chromosomes X or Y, probes related to nucleotides and polypeptides, and probes that did not match gene regions.

[0047] S304. Differential methylation analysis was performed on OSCC tissues and normal oral tissues in the TCGA database using R software. The screening conditions for differential sites were |logFC|>0.1, P<0.05 and false discovery rate (FDR)<0.05. P was the p value of the difference between normal tissues and OSCC tissues in the cohort with the most comprehensive information and the longest observation time among multiple cohorts.

[0048] S305, run the R software package "Meta R" to recalculate the OSCC differential DNA methylation sites in multiple different cohorts to obtain the Meta P value, and use the Benjamini-Hochberg method to correct the Meta P value obtained for each site, the FDR is 5%, the setting standard for the OSCC significant differential DNA methylation site is a single CpG: |logFC|> 0.1, FDR < 0.05, and output the OSCC significant differential DNA methylation site. Exemplarily, the OSCC significant differential DNA methylation site results can be presented in the form of heat maps and volcano maps using the R software packages "pheatmap" and "ggplot".

[0049] As an optional implementation, step S102 specifically includes the following steps:

[0050] S401, selecting the first N disulfide death-related DNA methylation sites from the differential DNA methylation site set for analysis, and merging the clinical data of M patients with the N disulfide death-related DNA methylation sites using R software to obtain merged data. In this embodiment, the value of N is 100, and the value of M is 365.

[0051] S402. Using R software packages "survival" and "survminer" with survival status as the prognostic type and P < 0.05 as the threshold, multifactorial COX regression analysis was performed on the merged data to screen out the disulfide death-related DNA methylation sites that are closely related to the survival prognosis of OSCC patients, calculate their hazard ratio (HR) and 95% confidence interval (95% CI), and draw a hazard ratio forest map. In some embodiments, the hazard ratio forest map can be drawn using the R software package "ggplot".

[0052] S403. A model was constructed based on the disulfide death DNA methylation level and the corresponding COX regression coefficient, which is closely related to the survival prognosis of OSCC patients. The risk score formula is as follows:

[0053]

[0054] Where N is the number of prognosis-related DNA methylation sites, Meth i is the DNA methylation level, Coef i is the COX regression coefficient.

[0055] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma, characterized in that: The method comprises the following steps: S101, obtaining a set of differential DNA methylation sites associated with disulfide death; S102. Construct a disulfide death-related DNA methylation prognostic model for OSCC (oral squamous cell carcinoma) based on differential DNA methylation sites.

2. The method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma according to claim 1, characterized in that: Step S101 specifically includes the following steps: S201. Screen out the sites with high or low methylation in multiple cohorts from the OSCC significantly differentially expressed DNA methylation sites, and then screen out the methylation sites located in the promoter region; S202, obtaining disulfide death-related genes from whole-genome CRISPR-Cas9 sequencing results; S203. Using R software, the genes corresponding to the OSCC differential DNA methylation sites in the promoter region are intersected with the disulfide death-related genes to obtain a differential DNA methylation site set.

3. The method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma according to claim 2, characterized in that: The promoter region includes 5'UTR, TSS200, TSS1500 and 1st Exon.

4. The method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma according to claim 2, characterized in that: OSCC significantly differentially expressed DNA methylation sites were obtained by the following steps: S301. Obtain DNA methylation data and clinical data of HNSCC (head and neck squamous cell carcinoma) patients, and delete DNA methylation data without clinical information and non-oral sites; S302, acquiring a DNA methylation data set based on preset inclusion criteria; S303, integrating all DNA methylation data obtained in steps S301 and S302, and then performing preprocessing, quality control filtering and normalization on the integrated DNA methylation data; S304. Differential methylation analysis was performed on OSCC tissues and normal oral tissues in the TCGA database using R software. The screening conditions for differential sites were |logFC|>0.1, P<0.05 and false discovery rate (FDR)<0.

05. S305. Run R software to recalculate the OSCC differential DNA methylation sites in multiple different cohorts to obtain MetaP values, and use the Benjamini-Hochberg method to correct the Meta P value obtained for each site. The FDR is 5%. The setting criteria for OSCC significantly differential DNA methylation sites are single CpG: |logFC|>0.1, FDR<0.05, and output OSCC significantly differential DNA methylation sites.

5. The method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma according to claim 4, characterized in that: The preset inclusion criteria include: oral tissue of OSCC patients, the same DNA methylation sequencing platform, normal oral tissue, and patients who have not received chemoradiotherapy or biological treatment.

6. The method for constructing a prognostic model of disulfide death-related DNA methylation in oral squamous cell carcinoma according to claim 2, characterized in that: Step S102 specifically includes the following steps: S401, selecting the top N disulfide death-related DNA methylation sites from the differential DNA methylation site set for analysis, and merging the clinical data of M patients with the N disulfide death-related DNA methylation sites using R software to obtain merged data; S402. Using R software, we took survival status as the prognostic type and P<0.05 as the threshold value to perform multivariate COX regression analysis on the combined data, screened out the disulfide death-related DNA methylation sites that were closely related to the survival prognosis of OSCC patients, calculated their hazard ratio (HR) and 95% confidence interval (95% CI), and drew a hazard ratio forest plot; S403. A model was constructed based on the disulfide death DNA methylation level and the corresponding COX regression coefficient, which is closely related to the survival prognosis of OSCC patients. The risk score formula is as follows: Where N is the number of prognosis-related DNA methylation sites, Meth i is the DNA methylation level, Coef i is the COX regression coefficient.